UPDATE: Jefferies Raises PT on Thermo Fisher Scientific on Pro-Forma Financial Model
In a report published Wednesday, Jefferies analyst Brandon Couillard reiterated a Buy rating on Thermo Fisher Scientific (NYSE: TMO), and raised the price target from $80.00 to $95.00.
In the report, Couillard noted, “We are publishing our pro-forma model and revised EPS forecasts to reflect the estimated impact of the pending LIFE acquisition. Our revised 2013 EPS forecast ($5.35 from $5.40) removes the effects of $600M of previously anticipated share repurchases. We are raising our 2014 EPS forecast to $6.95 (from $5.80) to account for $1.15 of anticipated LIFE-related EPS accretion. Our PT moves to $95 (from $80) on higher cash flow forecasts.”
Thermo Fisher Scientific closed on Tuesday at $81.82.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.